Clinical trial
Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene
NCT06443034 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- June 30, 2024
- Completion date
- December 30, 2024
- Enrollment
- 124 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
apol1 associated kidney disease, focal segmental glomerulosclerosis, nephrotic syndrome